Segura Dávila, Karen

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology

Vall Hebron Institut de Recerca

Segura Dávila, Karen

Institutions of which they are part

Administration and Management
Clinical Neuroimmunology

Vall Hebron Institut de Recerca

Related news

Dr. Xavier Montalban, Dr. Mar Tintoré and Dr. René Carvajal

Age and treatment may predict risk of multiple sclerosis reactivation

A Vall d’Hebron study, carried out at Cemcat, shows that the risk of inflammatory activity increases after discontinuing treatment, but is considerably reduced in people over 60 years of age.

Viva in Vitro and Vall d’Hebron will study biomarkers in multiple sclerosis

The project will analyse the functional activation of the NLRP3 inflammasome to advance the early identification of patients at risk of insufficient response to S1P receptor-modulating therapies.

Ovarian reserve does not predict the course of multiple sclerosis

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.